Market Place
Sourcing Support
All News #Library
Biotech
Elevar Therapeutics Submits Lirafugratinib For FDA Review
30 Mar 2026 //
GLOBENEWSWIRE
Elevar Pharma Resubmits Rivoceranib-Camrelizumab Combo NDA
30 Jan 2026 //
GLOBENEWSWIRE
Elevar Therapeutics Names Dong-Gun Kim CEO for Post-NDA Push
29 Jan 2026 //
GLOBENEWSWIRE
Elevar Pharma Seeks FDA Approval For Lirafugratinib
28 Jan 2026 //
GLOBENEWSWIRE
Elevar Therapeutics Publishes CARES-310 Study Final Analysis
03 Dec 2025 //
GLOBENEWSWIRE
FDA rejects Hengrui, Elevar`s PD-1 cancer drug combo—again
22 Mar 2025 //
FIERCE PHARMA
Elevar Shares Post-Hoc CARES-310 Data In Hepatocellular Cancer
24 Jan 2025 //
GLOBENEWSWIRE
Elevar Announces FDA Acceptance Of Rivoceranib For HCC Treatment
21 Oct 2024 //
GLOBENEWSWIRE
Elevar Resubmits NDA For Camrelizumab Plus Rivoceranib In HCC
23 Sep 2024 //
GLOBENEWSWIRE
Elevar Presents Rivoceranib Plus Camrelizumab Data At ESMO 2024
12 Sep 2024 //
GLOBENEWSWIRE
Elevar Therapeutics Median OS 23.8 Mos In 1L Unresectable HCC
30 May 2024 //
GLOBENEWSWIRE
Elevar Therapeutics To Present Two Posters From Phase 3 CARES-310 Study
18 Jan 2024 //
GLOBENEWSWIRE
Jiangsu Hengrui and Elevar Therapeutics Announce Agreement for Camrelizumab
17 Oct 2023 //
GLOBENEWSWIRE
Elevar Announces Acceptance for Filing of NDA for Rivoceranib with Camrelizumab
17 Jul 2023 //
GLOBENEWSWIRE
Elevar Submits NDA to FDA for Combination of Rivoceranib and Camrelizumab
17 May 2023 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.